Mapping α2 adrenoceptors of the human brain with11C-yohimbine

Journal of Nuclear Medicine

Volumn 56, Issue 3, 2015, Pages 392-398

  Nahimi, Adjmal ^a   Jakobsen, Steen ^a   Munk, Ole L ^a   Vang, Kim ^a   Phan, Jenny A ^a   Rodell, Anders ^a   Gjedde, Albert ^a,b,c,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

11c yohimbine; Brain; Noradrenaline; Positron emission tomography; 2 adrenoceptors

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CYTOCHROME P450 2D6; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YOHIMBINE C 11; CARBON; LIGAND; YOHIMBINE;

ADULT; ARTERIAL BLOOD; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MAPPING; CORPUS CALLOSUM; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RIGHT HEMISPHERE; SUBCORTEX; VOLUME OF DISTRIBUTION; BRAIN; BRAIN CORTEX; DIAGNOSTIC USE; IMAGE PROCESSING; METABOLISM; SCINTISCANNING; STATISTICAL MODEL; TIME;

ADULT; BRAIN; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CYTOCHROME P-450 CYP2D6; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIGANDS; MALE; MODELS, STATISTICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS; YOHIMBINE;

EID: 84928155175     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.145565     Document Type: Article

References (27)

1. 2-adrenoceptors. J Neurochem. 2001;78:685-693.
2. Weinshank RL, Zgombick JM, Macchi M, et al. Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor. Mol Pharmacol. 1990;38:681-688.
3. Kobilka BK, Matsui H, Kobilka TS, et al. Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science. 1987;238:650-656.
4. Lomasney JW, Lorenz W, Allen LF, et al. Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA. 1990;87:5094-5098.
5. Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992;6:832-839.
6. Pascual J, del Arco C, González AM, Pazos A. Quantitative light microscopic autoradiographic localization of α2-adrenoceptors in the human brain. Brain Res. 1992;585:116-127.
7. Perälä M, Hirvonen H, Kalimo H. Differential expression of two α2-adrenergic receptor subtype mRNAs in human tissues. Brain Res Mol Brain Res. 1992;16:57-63.
8. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev. 2004;45:38-78.
9. 11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. Synapse. 2006;59:463-471.
10. 11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist. Bioorg Med Chem. 2006;14:4526-4534.
11. 11C]yohimbine. J Nucl Med. 2006;47:2008-2015.
12. Phan JA, Jakobsen S, Simonsen M, Nahimi A, Landau AM, Gjedde A. Amphetamine-induced inhibition of [C-11]yohimbine binding in rat brain. J Cereb Blood Flow Metab. 2012;32(suppl):S98-S99.
13. Hammers A, Koepp MJ, Free SL, et al. Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp. 2002;15:165-174.
14. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
15. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol. 2005;63:1-20.
16. Gjedde A, Bauer WR, Wong DF. Neurokinetics: The Dynamics of Neurobiology in Vivo. New York, NY: Springer; 2010:103-126.
17. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982;257:237-274.
18. 18F]FDOPA in humans. J Cereb Blood Flow Metab. 1993;13:668-675.
19. Gjedde A, Gee AD, Smith DF. Basic CNS drug transport and binding kinetics in vivo. In: Begley DJ, Bradbury MW, Kreuter J, eds. The Blood-Brain Barrier and Drug Delivery to the CNS. New York, NY: Marcel Dekker; 2000:225-242.
20. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
21. 18F]fluoro-L-DOPA in rat. J Cereb Blood Flow Metab. 1990;10:707-719.
22. Gjedde A, Kumakura Y, Cumming P, Linnet J, Møller A. Inverted-U-shaped correlation between dopamine receptor availability in striatum and sensation seeking. Proc Natl Acad Sci USA. 2010;107:3870-3875.
23. 11C]RS-15385-197 as a positron emission tomography radioligand for central a2-adrenoceptors. Eur J Nucl Med. 2000;27:475-484.
24. Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68:854-860.
25. Le Corre P, Dollo G, Chevanne F, Le Verge R. Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci. 1999;9:79-84.
26. Berlan M, Verge RL, Galitzky J, Corre PL. α2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine. Br J Pharmacol. 1993;108:927-932.
27. Le Corre PA, Peskind ER, Chevanne F, Raskind MA, Le Verge R. Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Eur J Clin Pharmacol. 1997;52:135-138.